Executive Summary
Leidos Biomedical Research Inc., a Leidos Holdings subsidiary, secured a $327M obligated delivery order from NIH NCI, with potential upside to $776M via options, providing reliable FY26-FY27 revenue in health R&D services. This cost-plus-fixed-fee award under full competition signals strong positioning amid HHS priorities. Early low outlay ($24M) warrants monitoring for execution toward full value.
Tracking the trend? Catch up on the prior HHS & Healthcare Contracts Intelligence digest from January 23, 2026.
Investment Signals(1)
- Leidos wins major NIH NCI R&D delivery order(HIGH)▲
Award of $327M obligation (potential $776M total) for operational tasks enhances revenue visibility through 2027.
Risk Flags(1)
- Execution[MEDIUM RISK]▼
Unexercised options represent $449M potential beyond current $327M obligation; low initial outlay of $24M vs. obligation.
Opportunities(1)
- ◆
Expansion to full $776M value via option exercises and potential extension to 2027-08-30.
Sector Themes(1)
- ◆
Large cost-plus-fixed-fee delivery order signals sustained HHS investment in life sciences R&D services (NAICS 541715).
Watch List(1)
- 👁
{"entity"=>"Leidos Holdings, Inc.", "reason"=>"Single large contract with $449M option upside and low initial outlay signals execution dependency.", "trigger"=>"Outlays exceeding 10% of obligation or option exercises"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC